About the Conference
Programme in development! The programme committee is working on a cutting edge scientific programme. Stay tuned for the preliminary programme.
For the first time ever, the EuroMeeting will be organised in parallel with the Clinical Forum. This will afford delegates unparalleled opportunities to interact and network with qualified professionals from throughout Europe and the world, and to meet a wealth of exhibiting companies, all under one roof. You will meet professionals from the pharmaceutical and biotech industries, CROs, clinical trial sites, health regulatory agencies and delegates from academia and patient organisations, and more.
Director, Legal Department, Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Poland. Graduate of the Legal and Administration Department, University of Warsaw, Poland.
During most of her professional career she has been involved in international health issues, especially in collaborative projects with the United States, Canada and the World Health Organization.
Since the accession of Poland to the European Union in 2004 she has been representing Poland as an expert in the Council Working Party on Pharmaceuticals and Medical Devices working on the EU pharmaceutical legislation proposals, she has also participated in the activities of the Heads of Agencies and has been a member of EMACOLEX.
Christopher A. Viehbacher
Christopher A. Viehbacher is a certified public accountant and a graduate of Queens University (Ontario - Canada). He holds German and Canadian nationalities. Since December 2008, he is Chief Executive Officer, Sanofi. He is a Board member and member of the Strategy Committee. He is also Chairman of Genzyme, which Sanofi acquired in February 2011.
After starting his career in finance at PriceWaterhouseCoopers, Christopher joined GlaxoSmithKline (GSK) in 1988. Throughout his 20 year tenure he worked across Europe, the United States and Canada. His last position was President, Pharmaceutical Operations North America. He was a member of the board and Co-Chairman of the Portfolio Management Board.
Christopher was elected President of the EFPIA (European Federation of Pharmaceutical Industries and Associations) in June 2013. He was Chairman of PhRMA in the US between 2010 –2012 and since February 2011, he is Chair of the CEO Roundtable on Cancer. He received the French Legion of Honour in 2003 and the 2012 Pasteur Foundation Award in recognition of his leadership role in health. Christopher is a member of International Business Council (WEF) and the Board of Visitors of Fuqua School of Business, Duke University.